What Is Menopause and Its Disorders?
Menopause is the permanent, irreversible end of a woman’s menstrual cycles, confirmed retrospectively after 12 consecutive months without a period, resulting from the natural decline and eventual cessation of ovarian hormone production. It is not a disease — it is a universal biological transition that every woman who lives long enough will experience. But the word menopause in everyday usage has come to describe far more than a single calendar milestone: it encompasses the entire continuum of perimenopause, the menopause transition itself, and the decades of postmenopausal life that follow, all of which are shaped by estrogen deficiency and carry their own distinct clinical profile. In the United States in 2026, that continuum affects a staggering number of women: an estimated 6,000 American women reach menopause every single day, adding up to approximately 1.3 million new menopause transitions annually. With women now routinely living well into their 80s and beyond, the average American woman can expect to spend roughly 40% of her entire life in the postmenopausal state — a demographic reality that makes the quality of menopause care a defining issue for the long-term health of the American female population. Yet despite this enormous and growing scale, menopause in the United States remains profoundly underfunded, undertreated, and in too many clinical settings, barely acknowledged.
What elevates menopause disorders from a personal inconvenience to a full-scale American public health and economic crisis in 2026 is the weight of the downstream consequences. The hormonal shifts of the menopausal transition do not simply cause hot flashes and disrupted sleep — they fundamentally alter the cardiovascular, skeletal, metabolic, cognitive, and psychological architecture of a woman’s body, creating an elevated risk environment that, left unmanaged, drives enormous healthcare utilization and cost for decades after the final menstrual period. A landmark 2023 Mayo Clinic study estimated that menopause symptoms cost the US economy more than $26 billion every year — combining $24.8 billion in direct medical expenditures with $1.8 billion in lost workplace productivity from absenteeism and presenteeism alone. And that figure does not include the cascading costs of the chronic diseases that menopause accelerates: osteoporosis, cardiovascular disease, type 2 diabetes, Alzheimer’s disease, and the mental health burden that accompanies the transition at dramatically elevated rates. In 2026, menopause is not merely a passage — it is a pivot point in women’s health that the American healthcare system has been systematically slow to address, and the statistics make the cost of that failure impossible to ignore.
Interesting Key Facts About Menopause Disorders in the US 2026
Before examining the statistics in depth, these core facts about menopause and its associated disorders provide the essential clinical and demographic context for understanding the scale and significance of the issue in America today.
| Key Fact | Detail |
|---|---|
| Definition | Menopause is confirmed after 12 consecutive months without menstruation, resulting from the cessation of ovarian hormone production |
| Average age of menopause in the US | 51.4 years — the median age at which the final menstrual period occurs in American women |
| Most common onset range | Between ages 45 and 56 in the majority of US women |
| Women entering menopause daily in the US | Approximately 6,000 women per day — roughly 1.3 million per year |
| Total US women aged 50 and older | 64 million — more than half the US female population is age 40 and above |
| Projected global menopausal women by 2025 | 1.1 billion women worldwide are or will be menopausal due to increasing life expectancy |
| Postmenopausal life expectancy | The average US woman can expect to spend 40% of her life in postmenopause |
| Perimenopause duration | Average of 4 years — though it can last anywhere from a few months to 10 years |
| Symptom burden | Between 80%–96% of women experience symptoms during the menopausal transition |
| Premature menopause prevalence in the US | 1.7% of US women experience premature menopause (before age 40) — per NHANES data |
| Early menopause prevalence in the US | 3.4% of US women experience early menopause (ages 40–44) — per NHANES data |
| Smoking and menopause timing | Current or former smokers reach menopause approximately 2 years earlier than non-smokers |
| Cardiovascular disease post-menopause | CVD is the leading cause of death in postmenopausal American women |
| Osteoporosis risk post-menopause | 1 in 5 US women over age 60 develops osteoporosis; 1 in 2 will experience low bone mass (osteopenia) |
| Certified menopause practitioners in the US | Only ~1,300 NAMS-certified practitioners nationwide — a critically insufficient workforce for the scale of need |
| Menopause curriculum in medical training | More than 90% of OB/GYN residency program directors agree residents should receive standardized menopause training — yet fewer than 1 in 3 programs actually provide it |
| US menopause market value (2024) | $5.56 billion — projected to reach $8.58 billion by 2033 |
| Global menopause market (2024) | $17.66 billion globally — projected to grow to $27.63 billion by 2030 |
Source: NCBI StatPearls — Menopause (December 2023, StatPearls Publishing 2025); CDC — National Health and Nutrition Examination Survey (NHANES); The Menopause Society (NAMS) — Annual Meeting Presentations 2024; Mayo Clinic Proceedings — Faubion et al. (2023)
The key facts above define the scope of what menopause represents in America in 2026 — and the numbers are genuinely startling in their scale and their implications. The reality that 6,000 American women enter menopause every day but only roughly 1,300 certified practitioners are equipped to treat this transition comprehensively is perhaps the single sharpest illustration of how badly the US healthcare system has failed to scale up for the fastest-growing demographic of patients in the country. The 40% of life spent postmenopausal figure is particularly striking: for a woman who reaches menopause at 51 and lives to 82, that is more than three full decades of life governed by estrogen deficiency and its consequences — three decades during which cardiovascular risk rises, bone density falls, cognitive protection weakens, and metabolic health deteriorates, all in the absence of the estrogen that had been protecting her since puberty. The gap in medical school training — with fewer than 1 in 3 OB/GYN residencies offering any standardized menopause curriculum — is not just an educational gap. It is a direct and measurable driver of the undertreated suffering experienced by tens of millions of American women navigating the menopausal transition with inadequate clinical support in 2026.
Menopause Prevalence and Onset Statistics in the US 2026
Understanding exactly how many American women are currently navigating some phase of the menopausal transition — and when and how it typically begins — provides the essential population-level context for everything that follows.
| Prevalence / Onset Metric | Data |
|---|---|
| Total US women age 50 and older | 64 million (US Census Bureau data) |
| Total US women age 40 and older | More than half of the entire US female population |
| Women entering menopause annually in the US | Approximately 1.3–2 million per year |
| Women entering menopause daily in the US | Approximately 6,000 women every day |
| Estimated US women in menopause by 2025 | 54 million (Joylux / femtech market estimates) |
| Average age at natural menopause in the US | 51.4 years (per NCBI StatPearls, updated StatPearls Publishing 2025) |
| Most common age range for menopause onset | Ages 45–56 for the majority of American women |
| Largest single age group entering menopause | Women aged 50–54 — approximately 30% of menopausal/postmenopausal US women entered menopause in this window (YouGov/Statista, 2023) |
| Premature menopause rate (before age 40) in the US | 1.7% of US women — per NHANES (1999–2014) |
| Early menopause rate (ages 40–44) in the US | 3.4% of US women — per NHANES (1999–2014) |
| Perimenopause — typical start age | Mid-40s — though changes can begin as early as the mid-to-late 30s in some women |
| Late perimenopause age | Typically late 40s to early 50s — characterized by increasingly irregular periods |
| Perimenopause average duration | Approximately 4 years — range of a few months to 10 years |
| Percentage of workforce in menopause transition (2024) | Approximately 25% of the entire US workforce was in some phase of menopause transition as of 2024 |
| Women aged 45–54 in the US labor force (2024) | 76.8% are actively participating in the workforce |
| Menopause as a proportion of total US workforce | Women aged 45–54 make up approximately 9.5% of the entire US workforce |
Source: NCBI StatPearls — Menopause (StatPearls Publishing 2025); CDC NHANES (1999–2014) — Premature and Early Menopause Trends; YouGov/Statista Survey 2023 — Age Started Menopause, US Women; FP Analytics/Bayer — United States: Health and Economic Impacts of Menopause (July 2025); US Bureau of Labor Statistics (2024); Joylux femtech estimates (2025); US Census Bureau
The menopause prevalence data for the United States in 2026 draws a picture of an enormous and growing demographic that the healthcare system has persistently underserved. The 64 million American women aged 50 and older represents the core postmenopausal population, but the real scale of the challenge becomes clearer when you add the millions more women currently in perimenopause — typically beginning in their mid-40s and lasting an average of four years — who are already experiencing significant symptomatic burden without having technically reached the one-year amenorrhea threshold for a menopause diagnosis. The workforce data makes the public health imperative concrete in economic terms: with approximately 25% of the entire US workforce currently in some phase of the menopause transition, and 76.8% of women aged 45–54 still actively employed, menopause is not a retired woman’s health concern. It is happening right now, every day, in American offices, hospitals, schools, and factories — and the $26 billion annual economic cost documented by the Mayo Clinic is the direct price of a healthcare system that has not built adequate infrastructure to meet this moment.
Menopause Symptom Statistics in the US 2026
The breadth and severity of menopause symptoms affecting American women are far broader than the public conversation — which tends to focus almost exclusively on hot flashes — typically acknowledges.
| Symptom | Prevalence in Menopausal Women |
|---|---|
| Hot flashes (vasomotor symptoms) | 75%–81% of US women — the hallmark menopausal symptom |
| Night sweats | 80% of women in the menopausal transition |
| Overall vasomotor symptom (VMS) burden | 50%–80% of women experience moderate-to-severe VMS during the transition |
| Duration of hot flashes | Average of 7–11 years — for 40% of women in their 60s and 10%–15% in their 70s, hot flashes continue |
| Sleep disturbances | 70%–80% of women experience sleep problems — frequently occurring independently of hot flashes |
| Joint and muscular discomfort | 65.43% of women — the single highest-prevalence symptom in the landmark BMC Public Health 2024 meta-analysis of 482,067 women across 321 studies |
| Fatigue | 65%–75% of menopausal women in the US |
| Genitourinary syndrome of menopause (GSM) | Up to 50% of postmenopausal women — includes vaginal dryness, urinary incontinence, and painful intercourse |
| Cognitive symptoms (memory, concentration) | Widely reported; perimenopause is associated with measurable short-term memory and concentration difficulties |
| Mood disturbances (irritability, mood swings) | Approximately 51% of women in the SWAN study reported irritability, nervousness, or frequent mood changes during the transition |
| Anxiety symptoms | 23%–51% of women during perimenopause — with higher rates in clinic-based samples |
| Depression symptoms | 39% of women experience depression during or after menopause; perimenopausal women have a 40% higher risk for depressive symptoms vs. premenopausal women |
| Central obesity (weight redistribution) | 60%–70% of menopausal women in the US experience increased central obesity |
| Average VMS frequency in the US (global cross-sectional survey) | 3.8 VMS events per day for US women (vs. 4.6 in Europe and 3.0 in Japan) |
| Women with VMS who had never received hormone therapy | 81% of US participants in a global cross-sectional VMS survey had never received HT |
| 1 in 5 women with severe symptom burden | Report their symptoms are “worse than they could ever imagine” — Bonafide State of Menopause 2024 survey |
Source: NCBI StatPearls — Menopause (StatPearls Publishing 2025); BMC Public Health — Mapping Global Prevalence of Menopausal Symptoms Among Middle-Aged Women: A Systematic Review and Meta-Analysis (321 studies, 482,067 women; July 2024); PMC — Global Cross-Sectional Survey on VMS and QOL Burden
The symptom data for menopause in the United States tells a profoundly different story than the cultural narrative that has historically minimized this transition as an inconvenient but manageable passage. The BMC Public Health 2024 meta-analysis — the most comprehensive global symptom prevalence study ever conducted, incorporating 321 studies and 482,067 women — found that joint and muscular discomfort actually overtakes hot flashes as the highest-prevalence menopause symptom at 65.43%, a finding that most American women would find genuinely surprising given how rarely that symptom is discussed in public menopause education. The 7-to-11-year average duration of hot flashes is another number that consistently shocks women who expect this symptom to resolve within a year or two of their final period: nearly half of women in their 60s are still experiencing vasomotor symptoms that are disrupting their sleep, concentration, and daily functioning — and 10–15% are still dealing with them in their 70s. The 80% sleep disturbance rate is perhaps the most clinically underappreciated statistic in the entire menopause data set, because poor sleep is the driver of so many downstream health consequences — cognitive decline, immune dysfunction, cardiovascular disease, and mood disorders — that it creates a secondary cascade of health problems that extends far beyond the menopause transition itself.
Menopause Racial and Demographic Disparities in the US 2026
Menopause does not arrive on the same timeline or with the same intensity for all American women, and the data on racial and ethnic disparities is among the most important and least publicly discussed in the entire field.
| Demographic / Disparity Metric | Data |
|---|---|
| Average menopause age — general US population | 51 years (median) |
| Average menopause age — Black/African American women | ~49 years — approximately 2 years earlier than the national median |
| Average menopause age — Hispanic women | Approximately 2 years earlier than the national average |
| Earlier onset health implications | Earlier menopause means greater cumulative lifetime exposure to estrogen deficiency — increasing cardiovascular disease, osteoporosis, and cognitive decline risk |
| Vasomotor symptom frequency — Black women vs. White women | Black women report more intense and more frequent hot flashes and spend more time in the menopausal transition than non-Hispanic White women (SWAN study) |
| Vasomotor symptom burden — Hispanic women | Hispanic women also report greater VMS severity compared to White women (SWAN study) |
| VMS prevalence — Japanese American and Chinese American women | Report fewer vasomotor symptoms than White, Black, or Hispanic women (SWAN study) |
| Racial disparities in HRT access | Structural inequities in healthcare access contribute to lower rates of hormone therapy use among women of color |
| Black women — menopause transition duration | Spend considerably more time in the menopausal transition than non-Hispanic White women |
| Black and Hispanic women — healthcare system barriers | More likely to lack specialized menopause care access; disproportionately affected by insurance gaps |
| Earlier menopause and systemic inequality | Earlier menopause age in Black and Hispanic women is partly attributed to higher levels of chronic stress, environmental exposures, and socioeconomic disadvantage — a reflection of broader systemic inequalities (FP Analytics, 2025) |
| Native and Pacific Islander women | Understudied population with significant gaps in US menopause data |
| Surgical menopause | Women who undergo bilateral oophorectomy before natural menopause experience an abrupt, often more severe menopausal transition — associated with heightened cardiovascular and cognitive risk |
| Workplace support disparities | 42% of menopausal women say symptoms have impacted their career ambitions; impact is 27% higher for women under 50 — who are more likely to be in lower-income brackets with fewer workplace accommodations |
Source: Study of Women’s Health Across the Nation (SWAN) — longitudinal multi-ethnic cohort data; FP Analytics / Bayer — United States: The Health and Economic Impacts of Menopause (July 2025); Society for Women’s Health Research — Menopause Disparities: Prevalence and Health Impact Across the United States
The racial and demographic disparities data for menopause in the United States is one of the most underexamined — and most consequential — bodies of evidence in all of women’s health. The SWAN (Study of Women’s Health Across the Nation) study, the most rigorous long-term multi-ethnic menopause cohort study ever conducted in the US, has consistently documented that Black women experience menopause approximately 2 years earlier than White women, spend more total time in the menopausal transition, and report significantly more intense and disruptive vasomotor symptoms — findings with direct and serious implications for cumulative cardiovascular and bone health risk. Two additional years of estrogen deficiency, sustained over a lifetime, translates into measurably higher rates of cardiovascular events, osteoporotic fractures, and cognitive decline. The FP Analytics 2025 report is explicit about the mechanism underlying this disparity: earlier menopause onset in Black and Hispanic women is not merely a biological variation — it is partly a physiological reflection of the cumulative burden of chronic stress, environmental disadvantage, and systemic healthcare inequity. The implication is unambiguous: fixing the menopause care gap in America is inseparable from addressing the broader structural inequities that cause some American women to bear a disproportionate share of this transition’s health burden from a younger age and with fewer resources to manage it.
Menopause Cardiovascular and Bone Health Statistics in the US 2026
Two of the most serious long-term health consequences of menopause — cardiovascular disease and osteoporotic fractures — carry a healthcare cost and mortality burden that dwarfs the direct costs of the menopausal transition itself.
| Cardiovascular / Bone Health Metric | Data |
|---|---|
| Cardiovascular disease — postmenopausal women | CVD is the leading cause of death among postmenopausal US women |
| Estrogen deficiency and CVD risk | Declining estrogen at menopause increases LDL, decreases HDL, drives central obesity, and elevates cardiovascular risk in previously protected women |
| Alzheimer’s disease and menopause | Women represent two-thirds of all Alzheimer’s cases in the US; menopause-related estrogen decline may contribute to this disproportionate burden (2024 study data) |
| Osteoporosis — postmenopausal US women over 60 | 1 in 5 women over age 60 in the US develops osteoporosis |
| Low bone mass (osteopenia) — postmenopausal US women | 1 in 2 postmenopausal women experiences low bone mass |
| Americans with osteoporosis | Approximately 10.2 million — 80% are women |
| Women with osteopenia (at risk) | An additional 43.4 million Americans have osteopenia — the precursor to osteoporosis |
| Annual osteoporotic fractures in the US | Approximately 2 million fractures per year in the US are attributable to osteoporosis |
| Lifetime fracture risk — women over 50 | 1 in 2 women over age 50 will experience an osteoporosis-related fracture in her lifetime |
| Osteoporotic fracture hospitalization burden | In women 55 years and older, hospitalizations for osteoporotic fractures exceed those for MI, stroke, or breast cancer (individually) — Mayo Clinic Proceedings, 2015 |
| Annual direct costs of osteoporosis-related fractures (US) | Estimated $13.7–$20.3 billion in 2005; projected to reach $25.3 billion by 2025 — Bone Health & Osteoporosis Foundation |
| 12-month all-cause healthcare costs post-fracture | Exceeded $30,000 per patient — AJMC managed care database study |
| Direct + indirect societal costs of fractures (2018) | $57 billion — projected to increase to $95 billion by 2040 (Bone Health & Osteoporosis Foundation) |
| Osteoporosis treatment gap post-fracture | Fewer than 25% of women over 67 with an osteoporotic fracture undergo subsequent treatment or BMD measurement |
| Type 2 diabetes risk after menopause | Estrogen depletion contributes to unfavorable lipid changes and increased type 2 diabetes risk in postmenopausal US women |
Source: NCBI StatPearls — Menopause (StatPearls Publishing 2025); CDC — About Women and Heart Disease (April 2024); AJMC — Economic Implications of Osteoporotic Fractures in Postmenopausal Women; Mayo Clinic Proceedings — Singer et al. (2015) Osteoporotic Fracture Burden vs. Other Diseases; AJMC — Economic Burden of Osteoporotic Fractures in US Managed Care Enrollees (2020)
The cardiovascular and bone health data associated with menopause in the United States reflects a disease burden of truly extraordinary magnitude — and one that continues to grow as the postmenopausal US population expands. The finding that hospitalization rates for osteoporotic fractures in women over 55 exceed those for heart attack, stroke, or breast cancer individually is a comparison that most Americans — and, notably, many physicians — do not know. The collective 2 million annual osteoporotic fractures, combined with a lifetime fracture risk of 1 in 2 for women over 50 and a projected $95 billion in direct and indirect societal costs by 2040, make postmenopausal bone loss one of the most expensive single consequences of the menopause transition in American medicine. The cardiovascular picture is equally severe: the natural estrogen-mediated protection that keeps women’s cardiovascular risk lower than men’s throughout their reproductive years evaporates after menopause, and the subsequent rise in LDL, fall in HDL, increase in central obesity, and loss of vascular protection transforms the cardiovascular risk profile of postmenopausal American women into one that closely resembles that of men the same age. The emerging Alzheimer’s connection adds yet another layer: with women representing two-thirds of all US Alzheimer’s cases and recent 2024 research linking menopause-related estrogen decline to this disproportionate burden, the neurological consequences of this transition are increasingly impossible to overlook.
Menopause Mental Health and Quality of Life Statistics in the US 2026
The psychological and quality-of-life burden of menopause disorders in America is deeply significant, frequently overlooked by healthcare providers, and intimately connected to the biological mechanisms of estrogen withdrawal.
| Mental Health / Quality of Life Metric | Data |
|---|---|
| Perimenopausal women — risk for depressive symptoms vs. premenopausal | 40% higher risk for depressive symptoms during perimenopause |
| Depression during or after menopause | 39% of US women experience depression during or after the menopausal transition |
| VMS and depression risk — SWAN study | Women with vasomotor symptoms had a 1.5–2-fold increased risk of depression — with the strongest associations in those with the most frequent and bothersome symptoms |
| Anxiety symptoms during perimenopause | 23%–51% of women — higher in clinic-based samples vs. community samples |
| Mood disturbances (SWAN study) | 51% of women reported irritability, nervousness, or frequent mood changes during the menopausal transition |
| Women reporting negative impact on quality of life | The menopause-specific questionnaire (MENQOL) study of a US population-based sample found significant negative impact on health-related quality of life |
| Job performance impacted | Nearly 1 in 2 women (48%) say menopause symptoms have impacted their job performance — Bonafide State of Menopause 2024 |
| Career ambition impacted | 42% of menopausal women say symptoms have impacted their career ambitions |
| Age-based job impact disparity | Impact on job performance is 27% higher for women under 50 — who are earlier in the menopausal transition |
| Women who feel less productive/emotionally stable | 48% of women believe menopausal women are seen as less productive or emotionally stable in the workplace |
| Women spending less time with family/friends | Significant majority report social withdrawal due to unpredictable or severe symptoms |
| Sleep-VMS-mental health triad | SWAN data shows vasomotor symptoms, sleep disturbance, and fatigue consistently cluster together — this triad is the dominant symptom pattern in the most highly symptomatic women |
| Symptom unpredictability | The unpredictable, abrupt onset of vasomotor symptoms throughout the day — without warning — is cited as one of the most psychologically distressing features of the menopause transition |
| 1 in 5 women with extreme burden | Report symptoms are “worse than they could ever imagine” — Bonafide 2024 survey |
Source: Study of Women’s Health Across the Nation (SWAN) — longitudinal cohort; PMC — From Physiology to Psychology: An Integrative Review of Menopausal Syndrome (PMC12635657, 2025); BMC Public Health — Global Menopausal Symptom Meta-Analysis (321 studies, 482,067 women; 2024); Bonafide — State of Menopause 2024 Annual Survey; Journal of Affective Disorders — Badawy et al. (2024) Risk of Depression in Menopausal Stages; Maturitas — Williams et al. (2009) MENQOL US Population-Based Study
The mental health data for menopause disorders in the United States in 2026 makes a compelling and evidence-based case for treating the psychological dimension of the menopausal transition as a core clinical priority — not an afterthought. The 40% elevated risk for depressive symptoms during perimenopause is not a minor statistical signal: it represents millions of American women in their 40s and early 50s who are at substantially elevated risk for a mood disorder at precisely the moment in their professional and personal lives when they are most likely to be at or near the peak of their careers, managing complex family responsibilities, and least likely to attribute what they are feeling to hormonal flux. The SWAN study’s finding of a 1.5-to-2-fold elevated depression risk in women with significant vasomotor symptoms — and the consistent clustering of hot flashes, sleep disruption, fatigue, and psychological distress into a mutually reinforcing syndrome — explains why treating VMS is not just a matter of physical comfort. Unaddressed vasomotor symptoms drive sleep loss, which drives mood deterioration, which drives cognitive impairment, which drives workplace dysfunction, which drives economic loss. Every element of the $26 billion annual economic cost of menopause in the US flows, in part, from this cascade — and every part of it is, to varying degrees, preventable with timely, evidence-based clinical intervention.
Menopause Treatment Landscape and Care Gap Statistics in the US 2026
Despite the enormous and well-documented burden of menopause disorders, the treatment landscape in the United States in 2026 is characterized by dramatic underuse of effective therapies, deep disparities in access to care, and a healthcare system that has been chronically slow to build the infrastructure women need.
| Treatment / Care Gap Metric | Data |
|---|---|
| HRT use in the US — 1999 peak | Nearly 27% of menopausal women in the US used hormone replacement therapy |
| HRT use post-2002 WHI study (current rate) | Less than 5% of eligible menopausal US women currently use menopause hormone therapy (MHT) |
| Women with VMS who seek medical treatment | Only 1 in 4 women with vasomotor symptoms actually seeks medical treatment in the US |
| Women with VMS who never received HT (global survey, US) | 81% of US survey participants with VMS had never received any form of hormone therapy |
| Severe VMS duration | Average of 7–11 years — yet the vast majority of affected US women remain untreated |
| NAMS-certified menopause practitioners (US) | Only approximately 1,300 — a critically small number relative to the 54+ million women needing menopause care |
| OB/GYN residency programs with menopause curriculum | More than 90% of directors say training should include menopause — fewer than 1 in 3 programs actually provide it |
| States mandating menopause insurance coverage | As of 2025, only Illinois and Louisiana mandate that both public and private insurers cover medically necessary menopause treatment |
| US federal menopause research funding (Biden EO, March 2024) | $200 million for women’s health research overall — only $13 million designated specifically for menopause |
| Treatment market growth potential | BCG analysis (October 2025): better care could produce an eightfold increase in the menopause treatment market to $40 billion by 2030 |
| Non-hormonal treatments | Veozah (fezolinetant, Astellas) — FDA-approved 2023 for moderate-to-severe VMS; Elinzanetant (Bayer) in late-stage trials as of 2025 |
| California AB 360 (2025) | Requires state medical boards to survey physicians on menopause training as part of license-renewal — a new legislative approach to closing the provider knowledge gap |
| Treatment gap consequence | Untreated menopause disorders drive higher downstream spending on cardiovascular disease, osteoporosis, mental health care, and dementia — dwarfing the cost of treatment itself |
Source: STAT News — Menopause and HRT Underuse (December 2024); The Menopause Society — Hormone Therapy Usage Rates (September 2024 Annual Meeting); BCG — Closing the Menopause Care Gap: The Next Frontier in Women’s Health (October 2025); FP Analytics/Bayer — United States: Health and Economic Impacts of Menopause (July 2025); Grand View Research — US Menopause Market Report (2025)
The treatment landscape data for menopause in the United States reveals the full depth of a crisis that has been building for more than two decades. The collapse of hormone replacement therapy use from nearly 27% in 1999 to less than 5% today is one of the most consequential overreactions in modern American medical history — driven by a misinterpreted 2002 Women’s Health Initiative study that examined an older, non-symptomatic postmenopausal population and whose findings were broadly and incorrectly applied to women in their 40s and early 50s who could benefit most from timely hormonal intervention. The result is that tens of millions of American women with moderate-to-severe vasomotor symptoms lasting 7–11 years have been enduring an extended period of treatable suffering while the healthcare system offered little proactive guidance. The structural dimensions of the treatment gap are equally troubling: with only 2 states mandating insurance coverage for menopause treatment, and the entire country served by only ~1,300 certified menopause practitioners, the barriers to care are not just attitudinal — they are legal, geographic, financial, and institutional. The BCG October 2025 analysis estimates that closing the US menopause care gap with evidence-based diagnosis and treatment could grow the treatment market eightfold to $40 billion by 2030 — a figure that reflects not a healthcare cost, but an economic opportunity to prevent the far larger downstream costs of untreated menopause-related disease across millions of American women’s lifetimes.
Menopause Economic Burden Statistics in the US 2026
The financial cost of menopause disorders in the United States — spanning direct healthcare spending, lost workplace productivity, and the cascading costs of the chronic diseases the transition accelerates — has now been quantified at a scale that demands urgent policy response.
| Economic Metric | Data |
|---|---|
| Total annual economic cost of menopause in the US | More than $26 billion per year — Mayo Clinic study (Mayo Clinic Proceedings, 2023) |
| Direct annual medical expenditures from menopause symptoms | $24.8 billion per year |
| Annual workplace productivity losses from menopause | $1.8 billion per year — attributable to lost workdays from absenteeism and presenteeism |
| True economic cost — likely much larger | The $26 billion figure does NOT include costs from reduced hours, job changes, early retirement, or loss of employment |
| US women reporting adverse work outcomes from menopause | 13.4% of women aged 45–60 — Mayo Clinic survey (2021) |
| US women missing work due to menopause symptoms | ~10.8% of women aged 45–60 reported missing work |
| Annual osteoporosis fracture costs — projected 2025 | $25.3 billion per year — Bone Health & Osteoporosis Foundation (projected from 2007 analysis) |
| Total societal cost of osteoporotic fractures (2018) | $57 billion — direct and indirect combined; projected to reach $95 billion by 2040 |
| 12-month all-cause healthcare cost per fracture patient | Exceeds $30,000 — AJMC managed care enrollee database |
| Menopause treatment market — US (2024) | $5.56 billion — growing at 5.0% CAGR through 2033 |
| US share of global menopause supplement/OTC market | Approximately $6 billion of the $16.93 billion global market in 2023 |
| Projected US menopause market by 2033 | $8.58 billion — per Grand View Research 2025 analysis |
| MHT and non-hormonal biopharma revenue by 2030 | $16 billion if adequate diagnosis and treatment rates are achieved — BCG October 2025 |
| Potential menopause treatment market growth | Up to $40 billion by 2030 with system-wide care improvements — BCG October 2025 |
| Only 2 states with insurance mandates | Illinois and Louisiana are the only US states requiring insurance coverage for medically necessary menopause treatment (as of 2025) |
Source: Mayo Clinic Proceedings — Faubion et al. (2023) Impact of Menopause Symptoms on Women in the Workplace; Davis Wright Tremaine / Project W — Pulling Back the Curtain on Menopause (2024); FP Analytics/Bayer — US: Health and Economic Impacts of Menopause (July 2025)
The economic burden data for menopause in the United States produces numbers that should fundamentally change the way American policymakers, employers, and healthcare systems prioritize this issue. The $26 billion annual total cost documented by the Mayo Clinic — with $24.8 billion in direct medical costs and $1.8 billion in productivity losses — is already a staggering figure, but the researchers themselves are clear that it substantially understates the true economic impact: the calculation does not include the value of women who reduce their hours, change jobs to less demanding roles, or retire early due to unmanaged menopause symptoms. When you add to this the projected $95 billion societal cost of osteoporotic fractures by 2040 — a complication of estrogen deficiency that is substantially preventable with timely menopause management — the full economic picture becomes almost impossible to justify. The contrast with the investment side is stark: the March 2024 Biden Executive Order allocated just $13 million specifically to menopause research out of a $200 million women’s health package. The BCG October 2025 analysis offers the clearest summary of the economic logic: the path from the current undertreated status quo to an $40 billion treatment market by 2030 is not a projection of excess spending. It is a map of what appropriate investment in menopause care looks like when the alternative is tens of billions of dollars in preventable chronic disease costs borne by the women, the healthcare system, and the American economy across the next two decades.
Disclaimer: The data reports published on The Global Files are sourced from publicly available materials considered reliable. While efforts are made to ensure accuracy, no guarantees are provided regarding completeness or reliability. The Global Files is not liable for any errors, omissions, or damages resulting from the use of these reports.